3.2.1.113	diagnostics	MAN1C1 may be a useful prognostic biomarker and potential therapeutic target in clear cell renal cell carcinoma, with the potential to lead to better outcomes for patients with these poor prognosis malignancies	751168	
3.2.1.113	drug development	development of anti-cancer therapies	677921	
3.2.1.113	medicine	the class I alpha-mannosidases can be used as drug targets to inhibit the demannosylation of HBV, thereby improving the binding of the virus to DC-SIGN and disrupting the immune tolerance to prevent and treat viral infection	752329	
3.2.1.113	pharmacology	in triple KO (MAN1A1, MAN1A2, and MAN1B1) cells, Man9GlcNAc2 and Man8GlcNAc2 are the major N-glycan structures. The N-glycan structures on recombinant proteins expressed in triple KO cells are simplified and changed from complex types to high-mannose types at the protein level. The triple KO HEK293 cells are suitable for producing recombinant proteins, including lysosomal enzymes with high-mannose-type N-glycans. This approach should accelerate the production of biopharmaceutical proteins with homogenous glycans	751118